Physcion

• UNSPSC Description:

  Physcion (Parietin), an anthraquinone derivative derived from the traditional Chinese medicine rhubarb, is an effective oral active 6-phosphogluconate dehydrogenase inhibitor with blood-brain barrier permeability, with IC50 and Kd values of 38.5 μM and 26.0 μM, respectively. Additionally, Physcion is an inhibitor of the bTLR4/NF-κB signaling pathway, exhibiting anti-inflammatory, antibacterial, and anticancer effects, and can induce Apoptosis and Autophagy in cancer cells[1][2][3][4][5].

• Target Antigen:

  Antibiotic; Apoptosis; Autophagy; Bacterial; NF-κB; Toll-like Receptor (TLR)

• Type:

  Natural Products

• Related Pathways:

  Anti-infection;Apoptosis;Autophagy;Immunology/Inflammation;NF-κB

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Physcion.html

• Purity:

  99.10

• Solubility:

  DMF : 1 mg/mL (ultrasonic)|DMSO : 3.33 mg/mL (ultrasonic;warming;adjust pH to 9 with NaOH;heat to 60°C)|Ethanol : < 1 mg/mL|THF : 2.5 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C1C2=C(C=C(C)C=C2O)C(C3=CC(OC)=CC(O)=C13)=O

• Molecular Weight:

  284.26

• References & Citations:

  [1]Lin R, et al. 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nat Cell Biol. 2015 Nov;17(11):1484-96.|[2]Pang MJ, et al. Physcion, a naturally occurring anthraquinone derivative, induces apoptosis and autophagy in human nasopharyngeal carcinoma. Acta Pharmacol Sin. 2016 Dec;37(12):1623-1640.|[3]Dong X, et al. Physcion Protects Rats Against Cerebral Ischemia-Reperfusion Injury via Inhibition of TLR4/NF-kB Signaling Pathway. Drug Des Devel Ther. 2021 Jan 25;15:277-287.|[4]Liu X, et al. Physcion, a novel anthraquinone derivative against Chlamydia psittaci infection. Vet Microbiol. 2023 Apr;279:109664. doi: 10.1016/j.vetmic.2023.109664.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  521-61-9